NVO
$56.45
Revenue | $76857Mn |
Net Profits | $26503Mn |
Net Profit Margins | 34.48% |
Novo Nordisk A/s’s revenue jumped 12.93% since last year same period to $76857Mn in the Q2 2025. On a quarterly growth basis, Novo Nordisk A/s has generated -1.58% fall in its revenue since last 3-months.
Novo Nordisk A/s’s net profit jumped 32.18% since last year same period to $26503Mn in the Q2 2025. On a quarterly growth basis, Novo Nordisk A/s has generated -8.72% fall in its net profits since last 3-months.
Novo Nordisk A/s’s net profit margin jumped 17.05% since last year same period to 34.48% in the Q2 2025. On a quarterly growth basis, Novo Nordisk A/s has generated -7.26% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | 5.89 |
EPS Estimate Current Year | 5.89 |
Novo Nordisk A/s’s earning per share (EPS) estimates for the current quarter stand at 5.89 - a -1.83% fall from last quarter’s estimates.
Novo Nordisk A/s’s earning per share (EPS) estimates for the current year stand at 5.89.
Earning Per Share (EPS) | 0 |
Dividend Per Share (DPS) | 0.58 |
Novo Nordisk A/s’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Novo Nordisk A/s has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Novo Nordisk A/s declared 0.58 dividend per share during the earnings announcement for Q3 2025.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-08-06 | 6 | 5.96 | -0.67% |
2025-11-05 | 5.89 | 0 | -100% |
2025-05-07 | 6.07 | 6.53 | 7.58% |